Hemogenyx Pharmaceuticals (LON:HEMO) Trading Up 17.6% - What's Next?

Key Points

• Hemogenyx Pharmaceuticals' stock price rose 17.6% during Monday's trading, reaching GBX 1,230 ($16.68) at its peak, significantly higher than its previous close of GBX 1,010 ($13.69).
• The trading volume surged by 144%, with 143,993 shares changing hands compared to the average of 59,083 shares.
• Hemogenyx is a preclinical-stage biotechnology company focusing on treatments for blood diseases, including therapies for acute myeloid leukaemia and bone marrow transplants.

Hemogenyx Pharmaceuticals Plc (LON:HEMO - Get Free Report)'s share price was up 17.6% during mid-day trading on Monday . The company traded as high as GBX 1,230 ($16.67) and last traded at GBX 1,188 ($16.10). Approximately 143,993 shares were traded during trading, an increase of 144% from the average daily volume of 59,083 shares. The stock had previously closed at GBX 1,010 ($13.69).

Hemogenyx Pharmaceuticals Trading Down 4.2%

The company has a market capitalization of £69.96 million, a price-to-earnings ratio of -817.23 and a beta of 3.14. The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 90.87. The business's 50 day moving average price is GBX 396.60 and its two-hundred day moving average price is GBX 256.67.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.